ArticleProceedings of the National Academy of Sciences of the United States of America2024

A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.

Regina Cencic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.